Biotherapeutics company developing T-cell-engaging immunotherapies for solid tumors
Biotherapeutics company developing T-cell-engaging immunotherapies for solid tumors. Its technology aims to separate tumor killing from systemic immune activation, improving efficacy while limiting toxicity. Founded in 2025 with technology licensed from Seattle Children's Research Institute.